EGFR and non-small cell lung carcinoma: Based on the promising results of several clinical trials, the National Comprehensive Cancer Network (NCCN) has recommended EGFR-TKIs as standard therapy for advanced NSCLC patients with EGFR sensitive mutations (3–6).